Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.
A Irem SonmezAmmar AlmorsyLaura B RamseyJeffrey R StrawnPaul E CroarkinPublished in: Depression and anxiety (2020)
Notwithstanding numerous challenges, some of these agents represent potential candidate drugs for pediatric GAD. Further treatment development studies of agomelatine, eszopiclone, pimavanserin and riluzole for pediatric GAD also have the prospect of informing the understanding of GABAergic and glutamatergic function across development.